26 January 2021>: Clinical Research
Predictive Value of a Thyroid-Absorbed Dose with a Shorter Effective Half-Life on Efficacy in Graves Disease Patients Receiving Iodine-131 Therapy
Feng Yu BCEF , Ruiguo Zhang CDF , Guizhi Zhang B , Zhaowei Meng B , Xiaohua Liu B , Yajing He B , Jian Tan D , Renfei Wang ADG*DOI: 10.12659/MSM.928796
Med Sci Monit 2021; 27:e928796
Figure 1 The distribution of efficacy for Graves disease patients between the 2 groups with effective half-life (Teff) ≤3 d and Teff of >3 to ≤5 days.